The MCP-1 rs1024610 polymorphism was associated with increased risk of developing premature CAD in patients without type 2 diabetes mellitus.
The MCP-1 rs3760396 CC genotype was associated with low levels of gamma-glutamyl transpeptidase (P = 0.002) in premature CAD patients.
The MCP-1 rs1024610 TT genotype was associated with decreased risk of T2DM (P = 0.035) in premature CAD patients.
One MCP-1 haplotype (CATG) was associated with increased risk of developing premature CAD (OR = 1.44, P = 0.0019).